BSX
ChallengerBoston Scientific
$63.18
+2.32%
as of 13 Apr
Power Core
The moat in one sentence: Boston Scientific's competitive advantage is procedural workflow density, the accumulation of multiple product lines within the same hospital suite that creates switching costs through operational integration rather than through any single product's clinical superiority.
Direction of Movement
Multi-Vector Growth Driven by PFA and LAAC Expansion
ROC 200
-38.1%
BSX
Boston Scientific
$63.18
+2.32%
as of 13 Apr
DCF Fair Value: $70.73
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for interventional medical procedures worldwide. It operates through two primary segments: MedSurg, encompassing Endoscopy, Urology, and Neuromodulation; and Cardiovascular, including Cardiology and Peripheral Interventions. The company provides innovative solutions such as resolution clips, biliary stent systems, stents, electrocautery enhanced delivery systems, direct visualization systems, digital catheters, single-use duodenoscopes, endoluminal surgery tools, and infection prevention products for gastrointestinal conditions. Its portfolio also features less invasive devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal diagnostics, interventional oncology, neuromodulation for chronic pain, and incontinence treatment. Boston Scientific Corporation serves healthcare professionals and institutions globally, with foreign sales forming a significant portion of its business, focusing on minimally invasive therapies across cardiology, endoscopy, urology, and neuromodulation sectors. Founded in 1979 and headquartered in Marlborough, Massachusetts, it plays a vital role in advancing medical device innovation for improved patient outcomes in interventional specialties.